GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » QSAM Biosciences Inc (OTCPK:QSAM) » Definitions » Net-Net Working Capital

QSAM Biosciences (QSAM Biosciences) Net-Net Working Capital : $-0.04 (As of Dec. 2023)


View and export this data going back to 2011. Start your Free Trial

What is QSAM Biosciences Net-Net Working Capital?

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.

QSAM Biosciences's Net-Net Working Capital for the quarter that ended in Dec. 2023 was $-0.04.

The industry rank for QSAM Biosciences's Net-Net Working Capital or its related term are showing as below:

QSAM's Price-to-Net-Net-Working-Capital is not ranked *
in the Biotechnology industry.
Industry Median: 4.13
* Ranked among companies with meaningful Price-to-Net-Net-Working-Capital only.

QSAM Biosciences Net-Net Working Capital Historical Data

The historical data trend for QSAM Biosciences's Net-Net Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

QSAM Biosciences Net-Net Working Capital Chart

QSAM Biosciences Annual Data
Trend Mar14 Mar15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net-Net Working Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only -88.12 -10.40 -0.36 -0.91 -0.04

QSAM Biosciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Net-Net Working Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.91 -0.41 -0.53 -0.58 -0.04

Competitive Comparison of QSAM Biosciences's Net-Net Working Capital

For the Biotechnology subindustry, QSAM Biosciences's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


QSAM Biosciences's Price-to-Net-Net-Working-Capital Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, QSAM Biosciences's Price-to-Net-Net-Working-Capital distribution charts can be found below:

* The bar in red indicates where QSAM Biosciences's Price-to-Net-Net-Working-Capital falls into.



QSAM Biosciences Net-Net Working Capital Calculation

QSAM Biosciences's Net-Net Working Capital (NNWC) per share for the fiscal year that ended in Dec. 2023 is calculated as

Net-Net Working Capital(A: Dec. 2023 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(1.386+0.75 * 0+0.5 * 0-1.033
-0.509-0)/3.60938
=-0.04

QSAM Biosciences's Net-Net Working Capital (NNWC) per share for the quarter that ended in Dec. 2023 is calculated as

Net-Net Working Capital(Q: Dec. 2023 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(1.386+0.75 * 0+0.5 * 0-1.033
-0.509-0)/3.60938
=-0.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.

In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

This is a conservative way of estimating the company's value.


QSAM Biosciences  (OTCPK:QSAM) Net-Net Working Capital Explanation

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.


QSAM Biosciences Net-Net Working Capital Related Terms

Thank you for viewing the detailed overview of QSAM Biosciences's Net-Net Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


QSAM Biosciences (QSAM Biosciences) Business Description

Traded in Other Exchanges
N/A
Address
9442 Capital of Texas Highway North, Plaza 1, Suite 500, Austin, TX, USA, 78759
QSAM Biosciences Inc is a clinical-stage novel radiopharmaceutical company. The company is developing treatments for bone cancer and related diseases.
Executives
Adam King officer: Chief Financial Officer 9442 CAPITAL OF TEXAS HWY N, PLAZA 1, SUITE 500, AUSTIN TX 78759
Link Jr. Charles J director C/O NEWLINK GENETICS CORP., 2503 SOUTH LOOP DR., SUITE 5100, AIMES IA 50010
Adriann Sax director 7 DORSET COURT,, EAST BRUNSWICK, NJ 08816
David Charles Link director 2100 E 54TH STREET NORTH, SIOUX FALLS SD 57104
Douglas R Baum director, officer: CEO & Director 5000 RAFFEE COVE, AUSTIN TX 78731-1132
C Richard Piazza director, officer: Executive Chairman 2236 EAST MALL, SUITE 208, UNIVERSITY OF BRITISH COLUMBIA, VANCOUVER A1 V6T 1Z3
Checkmate Strategic Capital Holdings, Llc other: Member of 13(d) 10% owner grp 595 E. COLORADO BOULEVARD, SUITE 530, PASADENA CA 91101
Checkmate Strategic Capital 2, Llc 10 percent owner, other: See Explanation of Responses 595 E. COLORADO BOULEVARD, SUITE 530, PASADENA CA 91101
Checkmate Capital Group, Llc 10 percent owner, other: Member of 13(d) 10% owner grp 595 E. COLORADO BOULEVARD, SUITE 530, PASADENA CA 91101
Charles Thomas Paschall other: Member of 13(d) 10% owner grp 595 E. COLORADO BOULEVARD, SUITE 530, PASADENA CA 91101
Christopher M. Nelson director, officer: General Counsel 420 ROYAL PALM WAY, SUITE #100, PALM BEACH FL 33480
Scott W. Whitney director, other: Former Director 96 WINDSOR DRIVE, PINE BROOK NJ 07058
Kevin Bolin director, officer: Former Chairman & CEO 1081 ROSEDALE DRIVE, ATLANTA GA 30306
Tristan Peitz director, other: Former Director C/O Q2POWER TECHNOLOGIES, INC., 420 ROYAL PALM WAY, #100, PALM BEACH FL 33480
Joel David Mayersohn director 350 EAST LAS OLAS BLVD. #1150, FORT LAUDERDALE FL 33301

QSAM Biosciences (QSAM Biosciences) Headlines

From GuruFocus